Home | Orthoiodosupplementation | Body | Disease | Special | Overviews

Iodine and the Body

Iodine and the Breast  

• Aceves
• Arturi, Filetti
• Bezpalov
• Brown-Grant
• Cann
• Carrasco
• Cho
• Clur
• Debski
• Derry
• Douglass
• Eskin-Ghent
• Flechas
• Funahashi
• Garcia-Solis
• Giani
• Hartmann
• Howenstine
• Iwamoto
• Kapdi
• Kessler
• Kogai
• Lim, Moon
• Natarajan
• Park
• Perron
• Rillema
• Saraiva
• Sekiya
• Shrivastava
• Skibola
• Smyth
• Spitzweg
• Strum
• Tazebay
• Teas
• Torremante
• Turken
• Upadhyay
• Venturi
• Wapnir
• West

SPITZWEG

Mammary radioiodine accumulation due to functional sodium iodide symporter expression in a benign fibroadenoma.

Berger F, Unterholzner S, Diebold J, Knesewitsch P, Hahn K, Spitzweg C.

Biochem Biophys Res Commun. 2006 Nov 3;349(4):1258-63. Epub 2006 Sep 7.

[abstract only]

"The sodium iodide symporter (NIS) has been characterized to mediate the active transport of iodide not only in the thyroid gland but also in various non-thyroidal tissues, including lactating mammary gland and the majority of breast cancers, thereby offering the possibility of diagnostic and therapeutic radioiodine application in breast cancer. In this report, we present a 57-year-old patient with multifocal papillary thyroid carcinoma, who showed focal radioiodine accumulation in a lesion in the right breast on a posttherapy (131)I scan following radioiodine therapy. CT and MR-mammography showed a focal solid lesion in the right breast suggestive of a fibroadenoma, which was confirmed by histological examination. Immunostaining of paraffin-embedded tumor tissue sections using a human NIS antibody demonstrated NIS-specific immunoreactivity confined to epithelial cells of mammary ducts. In conclusion, in a thyroid cancer patient we identified a benign fibroadenoma of the breast expressing high levels of functionally active NIS protein as underlying cause of focal mammary radioiodine accumulation on a posttherapy (131)I scan. These data show for the first time that functional NIS expression is not restricted to lactating mammary gland and malignant breast tissue, but can also be detected in benign breast lesions, such as fibroadenomata of the breast."
 

Dexamethasone stimulation of retinoic Acid-induced sodium iodide symporter expression and cytotoxicity of 131-I in breast cancer cells.

Unterholzner S, Willhauck MJ, Cengic N, Schutz M, Goke B, Morris JC, Spitzweg C.

J Clin Endocrinol Metab. 2006 Jan;91(1):69-78. Epub 2005 Oct 18.

[abstract only]

"CONTEXT: The sodium iodide symporter (NIS) mediates the active iodide uptake in the thyroid gland as well as lactating breast tissue. Recently induction of functional NIS expression was reported in the estrogen receptor-positive human breast cancer cell line MCF-7 by all-trans retinoic acid (atRA) treatment in vitro and in vivo, which might offer the potential to treat breast cancer with radioiodine.

OBJECTIVE: In the current study, we examined the effect of dexamethasone (Dex) on atRA-induced NIS expression and therapeutic efficacy of 131-I in MCF-7 cells.

DESIGN: For this purpose, NIS mRNA and protein expression levels in MCF-7 cells were examined by Northern and Western blot analysis after incubation with Dex (10(-9) to 10(-7) m) in the presence of atRA (10(-6) m) as well as immunostaining using a mouse monoclonal human NIS-specific antibody. In addition, NIS functional activity was measured by iodide uptake and efflux assay, and in vitro cytotoxicity of 131-I was examined by in vitro clonogenic assay.

RESULTS: After incubation with Dex in the presence of atRA, NIS mRNA levels in MCF-7 cells were stimulated up to 11-fold in a concentration-dependent manner, whereas NIS protein levels increased up to 16-fold and iodide accumulation was stimulated up to 3- to 4-fold. Furthermore, iodide efflux was modestly decreased after stimulation with Dex in the presence of atRA. Furthermore, in the in vitro clonogenic assay, selective cytotoxicity of 131-I was significantly increased from approximately 17% in MCF-7 cells treated with atRA alone to 80% in MCF-7 cells treated with Dex in the presence of atRA.

CONCLUSION: Treatment with Dex in the presence of atRA significantly increases functional NIS expression levels in addition to inhibiting iodide efflux, resulting in an enhanced selective killing effect of 131-I in MCF-7 breast cancer cells."

More articles by Spitzweg

 Home | Orthoiodosupplementation | Body | Disease | Special Topics | Overviews  

The Iodine Group | Books | Disclaimers | Contact Us | Search  

  Copyright: Zoe, 2006.